Results 291 to 300 of about 9,725,589 (384)
Objective Tumornecrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to nonresponse or adverse effects.
Chuan Fu Yap +12 more
wiley +1 more source
Cell-based therapy in the treatment of musculoskeletal diseases. [PDF]
Trapana J +7 more
europepmc +1 more source
Objective Abnormalities in pain regulatory mechanisms are common in patients with rheumatoid arthritis (RA). We investigated whether pain sensitization changes after treatment with a disease‐modifying antirheumatic drug (DMARD) and explored associations between changes in pain sensitization and disease activity.
Burcu Aydemir +10 more
wiley +1 more source
A bibliometric and visualized analysis of extracellular vesicles in degenerative musculoskeletal diseases (from 2006 to 2024). [PDF]
Yang JJ +6 more
europepmc +1 more source
Objective We aimed to evaluate the influence of contrast‐enhanced dual‐energy computed tomography (CE‐DECT) in detecting and differentiating rheumatic joint diseases of the hand. Methods In this prospective study, patients with suspected arthritis of the hand were investigated consecutively alongside the standard clinical procedure.
Sevtap Tugce Ulas +9 more
wiley +1 more source
Correction: SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis
Bita Rostami-Afshari +12 more
doaj +1 more source
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received ...
Richard Furie +8 more
wiley +1 more source
Effects of aquatic high-intensity interval training on patient-reported outcome measures and quality-adjusted life-years in adults with rheumatic and musculoskeletal diseases: a secondary analysis of the AquaHigh randomised controlled trial. [PDF]
Bunæs-Næss H +5 more
europepmc +1 more source

